Edwards Lifesciences (NYSE:EW) Price Target Raised to $99.00 at Wells Fargo & Company

Edwards Lifesciences (NYSE:EW) had its target price lifted by Wells Fargo & Company from $94.00 to $99.00 in a research note published on Friday morning, Benzinga reports. Wells Fargo & Company currently has an overweight rating on the medical research company’s stock.

A number of other equities analysts have also recently commented on the company. Bank of America upgraded Edwards Lifesciences from a neutral rating to a buy rating in a report on Thursday, March 7th. Piper Sandler upped their target price on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock a neutral rating in a research note on Friday. Royal Bank of Canada raised their price target on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the company an outperform rating in a research report on Monday, April 15th. Mizuho upped their price objective on Edwards Lifesciences from $95.00 to $105.00 and gave the stock a buy rating in a research report on Thursday, April 11th. Finally, StockNews.com lowered Edwards Lifesciences from a buy rating to a hold rating in a report on Wednesday, March 20th. One research analyst has rated the stock with a sell rating, six have given a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and a consensus target price of $92.71.

Edwards Lifesciences Trading Down 0.6 %

Shares of EW stock opened at $85.95 on Friday. Edwards Lifesciences has a 1-year low of $60.57 and a 1-year high of $96.12. The firm has a market cap of $51.74 billion, a PE ratio of 37.05, a price-to-earnings-growth ratio of 4.28 and a beta of 1.05. The company has a 50-day moving average of $90.27 and a two-hundred day moving average of $79.06. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The firm had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.58 billion. On average, analysts predict that Edwards Lifesciences will post 2.76 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 1,715 shares of the business’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $90.98, for a total value of $156,030.70. Following the completion of the sale, the vice president now directly owns 17,213 shares of the company’s stock, valued at $1,566,038.74. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, VP Daniel J. Lippis sold 1,715 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $90.98, for a total transaction of $156,030.70. Following the transaction, the vice president now owns 17,213 shares in the company, valued at approximately $1,566,038.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Kieran Gallahue sold 3,058 shares of the business’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $87.61, for a total value of $267,911.38. Following the completion of the sale, the director now owns 67,219 shares of the company’s stock, valued at approximately $5,889,056.59. The disclosure for this sale can be found here. In the last quarter, insiders sold 194,004 shares of company stock worth $17,166,254. 1.27% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Caprock Group LLC increased its holdings in shares of Edwards Lifesciences by 4.8% in the third quarter. Caprock Group LLC now owns 8,611 shares of the medical research company’s stock valued at $597,000 after purchasing an additional 392 shares during the period. Oak Thistle LLC acquired a new position in Edwards Lifesciences in the 3rd quarter valued at $700,000. Czech National Bank raised its position in Edwards Lifesciences by 48.1% during the 3rd quarter. Czech National Bank now owns 106,252 shares of the medical research company’s stock worth $7,361,000 after buying an additional 34,487 shares during the last quarter. Asset Management One Co. Ltd. lifted its stake in shares of Edwards Lifesciences by 0.5% in the 3rd quarter. Asset Management One Co. Ltd. now owns 323,224 shares of the medical research company’s stock worth $22,393,000 after acquiring an additional 1,622 shares during the period. Finally, Connecticut Wealth Management LLC boosted its holdings in shares of Edwards Lifesciences by 66.7% in the third quarter. Connecticut Wealth Management LLC now owns 9,960 shares of the medical research company’s stock valued at $690,000 after acquiring an additional 3,985 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.